P

    Pliant Therapeutics Inc (PLRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.10
    -0.01 (-0.90%)

    Market Cap: $68.11M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    52%(13/25)
    Avg Surprise
    -1.17%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.36
    Range$-0.42 - $-0.32
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.38-4.1%
    60d ago$-0.38-4.1%
    30d ago$-0.36-0.1%
    7d ago$-0.37-1.4%
    Current$-0.36
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.40
    Range$-0.48 - $-0.34
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.40---
    Sep 26EST
    		-$-0.36---
    Jun 26
    Reported Aug 6
    		$-0.36$-0.33-9.09%Miss+49.3%
    Mar 26
    Reported May 11
    		$-0.32$-0.36+11.11%Beat+65.2%
    Dec 25
    Reported Mar 11
    		$-0.35$-0.42+14.97%Beat+56.8%
    Sep 25
    Reported Nov 6
    		$-0.43$-0.52+17.31%Beat+54.7%
    Jun 25
    Reported Aug 7
    		$-0.71$-0.62-14.52%Miss+22.8%
    Mar 25
    Reported May 8
    		$-0.92$-0.75-22.67%Miss-17.9%
    Dec 24
    Reported Mar 3
    		$-0.82$-0.96+14.15%Beat-18.8%
    Sep 24
    Reported Nov 7
    		$-0.95$-0.98+3.06%Beat-35.7%
    Jun 24
    Reported Aug 7
    		$-0.92$-0.85-8.24%Miss-31.4%
    Mar 24
    Reported May 6
    		$-0.78$-0.77-1.30%Miss-16.4%
    Dec 23
    Reported Feb 27
    		$-0.69$-0.81+14.81%Beat+4.2%
    Sep 23
    Reported Nov 9
    		$-0.70$-0.77+9.09%Beat-7.7%
    Jun 23
    Reported Aug 9
    		$-0.70$-0.69-1.45%Miss+14.6%
    Mar 23
    Reported May 9
    		$-0.67$-0.67+0.00%Beat+14.1%
    Dec 22
    Reported Mar 9
    		$-0.72$-0.70-2.86%Miss-5.9%
    Sep 22
    Reported Nov 8
    		$-0.65$-0.74+12.16%Beat+13.3%
    Jun 22
    Reported Aug 8
    		$-0.82$-0.81-1.23%Miss-28.1%
    Mar 22
    Reported May 9
    		$-0.78$-0.74-5.41%Miss-21.9%
    Dec 21
    Reported Feb 28
    		$-0.68$-0.76+10.53%Beat-25.9%
    Sep 21
    Reported Nov 9
    		$-0.75$-0.69-8.70%Miss-59.6%
    Jun 21
    Reported Aug 9
    		$-0.64$-0.67+4.48%Beat+54.0%
    Mar 21
    Reported May 10
    		$-0.64$-0.60-6.67%Miss-220.0%
    Dec 20
    Reported Mar 16
    		$-0.54$-0.71+23.94%Beat-157.1%
    Sep 20
    Reported Nov 10
    		$-0.47$-0.60+21.67%Beat-
    Jun 20
    Reported Aug 11
    		$-1.39$-0.68-104.41%Miss-
    Mar 20
    Reported Jun 3
    		$-0.20N/AN/ABeat-
    Jun 19
    Reported Jul 17
    		$-0.21$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.75EV/EBITDA-2.54x
    Price/FCF-0.96xFCF Yield-104.09%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-50.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage19.26x
    Current Ratio9.90xQuick Ratio9.90x
    Trading Statistics
    Beta1.27Avg Volume414.57K
    52-Week High$1.9552-Week Low$1.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.14
    SMA 20$1.10
    SMA 50$1.11
    SMA 200$1.24
    EMA 10$1.13
    EMA 20$1.12
    EMA 50$1.12
    EMA 200$1.27

    MACD

    Line: 0.01Signal: 0.01Hist: 0.00

    ADX

    ADX: 27.5+DI: 22.0-DI: 17.9

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down48.0
    PSAR$1.23

    Bollinger Bands

    Upper Band$1.20
    Lower Band$1.00
    %B Position1813%(Upper)
    Band Width0.49

    RSI (14-Day)

    Neutral
    47.9

    Momentum Oscillators

    Stoch %K47.6
    Stoch %D58.2
    Williams %R-61.9
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)-0.4
    MFI (14d)73.0

    Volatility Measures

    ATR (14d)$0.04(4.0%)
    StdDev (20d)0.05
    Hist Vol39.6%(Moderate)

    Volume Flow

    VWAP$1.10
    OBV-24.9M
    AD Line-44.8M
    CMF (20d)-0.164

    Volume Metrics

    Avg Vol (20d)427.2K
    Vol Ratio0.9x
    VWMA (20d)$1.11

    Pivot Points

    R3$1.18
    R2$1.16
    R1$1.14
    Pivot Point$1.12
    S1$1.10
    S2$1.08
    S3$1.06

    Advanced Oscillators

    TSI7.74
    Ultimate Osc46.8
    KST43.53

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$2.27M$0$0$0$4.84M$0
    Cost of Revenue$0$0$365,000$0$0$0$1.14M$0$0$0$464,000$0
    Gross Profit$0$0$-365,000$0$0$0$1.14M$0$0$0$4.38M$0
    Operating Expenses$23.86M$21.77M$23.58M$28.27M$45.59M$58.94M$53.32M$62.01M$60.64M$52.39M$47.04M$47.69M
    R&D$16.73M$13.58M$15.59M$17.94M$32.20M$43.44M$38.79M$47.75M$45.62M$37.15M$33.18M$32.34M
    SG&A$7.13M$8.19M$7.99M$10.33M$13.39M$15.50M$14.53M$14.26M$15.02M$15.25M$13.85M$15.35M
    Operating Income$-23,862,000$-21,772,000$-23,577,000$-28,269,000$-45,592,000$-58,935,000$-53,320,000$-62,014,000$-60,639,000$-52,392,000$-47,037,000$-47,685,000
    Interest Income$0$0$1.96M$0$0$0$0$0$0$0$0$0
    Interest Expense$-1,491,000$-1,732,000$136,000$-1,968,000$-2,292,000$-2,769,000$-3,588,000$-4,251,000$-4,785,000$-5,437,000$-5,928,000$-6,198,000
    Income Before Tax$-22,371,000$-20,040,000$-23,577,000$-26,301,000$-43,300,000$-56,166,000$-49,732,000$-57,763,000$-55,854,000$-46,955,000$-41,109,000$-41,487,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-22,371,000$-20,040,000$-23,577,000$-26,301,000$-43,300,000$-56,166,000$-49,732,000$-57,763,000$-55,854,000$-46,955,000$-41,109,000$-41,487,000
    EBITDA$-23,731,000$-21,091,000$-23,076,000$-27,498,000$-43,168,000$-57,125,000$-52,297,000$-60,481,000$-60,164,000$-50,788,000$-41,348,000$-50,940,000
    EBIT$-23,862,000$-21,772,000$-23,441,000$-28,269,000$-45,592,000$-58,935,000$-53,320,000$-62,014,000$-60,639,000$-52,392,000$-47,037,000$-47,685,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PLRX

    News

    Price to earnings forward of Pliant Therapeutics, Inc. – DUS:9PT

    This article provides the "Price to earnings forward" value for Pliant Therapeutics, Inc. (DUS:9PT) at the Dusseldorf Stock Exchange. It notes that the market is currently closed with no trades. The content primarily consists of navigation and boilerplate text from the TradingView platform.

    TradingView•8/21/26•
    Neutral

    Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

    Pliant Therapeutics (NASDAQ:PLRX), an unprofitable biopharmaceutical company, has a cash runway of about 2.2 years based on its current cash burn rate of US$71 million annually and US$158 million in cash reserves as of June 2026. While the company's cash burn decreased by 59% in the last year, its cash burn is approximately equal to its market capitalization of US$68 million, raising concerns about potential funding difficulties if it needs to raise more capital.

    Simply Wall Street•8/19/26•
    Somewhat-Bearish

    J.P. Morgan Maintains Pliant Therapeutics(PLRX.US) With Sell Rating

    J.P. Morgan has reiterated its Sell rating on Pliant Therapeutics (PLRX.US). The article does not provide further details regarding the rationale behind this rating or any financial metrics.

    Moomoo•8/19/26•
    Bearish

    BRIEF-Pliant Therapeutics Receives FDA Fast Track Designation For PLN-101095 In Combination With Pembrolizumab For The Treatment Of Ici-Refractory Solid Tumors

    Pliant Therapeutics has received FDA Fast Track Designation for its drug PLN-101095 when used in combination with Pembrolizumab for the treatment of ICI-refractory solid tumors. The company, trading under the symbol PLRX.O, expects to release data from its Phase 1a/1b FORTIFY trial for PLN-101095 in 2027. This designation aims to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.

    Bitget•8/19/26•
    Bullish

    Pliant Therapeutics (PLRX) Gains FDA Fast Track for PLN-101095 Amidst Challenging Valuation

    Pliant Therapeutics (PLRX) has received FDA Fast Track designation for its investigational drug PLN-101095, a novel therapy for solid tumors resistant to immune checkpoint inhibitors. Despite this positive regulatory news, the company faces significant valuation challenges with zero revenue and an effectively infinite Price-to-Sales ratio. Its low GF Score of 31/100 reflects profitability issues typical of a clinical-stage biotech, though its financial strength is rated highly.

    GuruFocus•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About PLRX

    Does PLRX pay dividends?
    Pliant Therapeutics Inc (PLRX) does not currently pay a regular dividend.
    What is PLRX's market cap?
    Pliant Therapeutics Inc (PLRX) has a market capitalization of $68.11M with a current stock price of $1.10.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In